Core Insights - BioVaxys Technology Corp. and SpayVac for Wildlife, Inc. have published results demonstrating the efficacy of the SpayVac immunocontraceptive vaccine, which reduced fertility in vaccinated deer to 11% compared to 86% in control animals [1][2] - The study involved 47 free-ranging red deer and confirmed the vaccine's effectiveness across three deer species, indicating broad applicability for managing deer populations [2] - The company is pursuing regulatory approval for SpayVac, targeting feral horses and free-ranging deer populations, with significant commercial potential anticipated due to the large deer population worldwide [2] Group 1: Vaccine Efficacy - A single dose of SpayVac vaccine significantly reduced fertility rates in deer, demonstrating long-lasting effects for 3 to 5 years [2] - The vaccine's technology utilizes a liposome-based delivery platform that enhances immune response [1][2] - SpayVac has shown clinical validation in three distinct deer species, indicating its potential for widespread use [2] Group 2: Market Potential - The commercial potential for SpayVac is significant, with expectations of a healthy royalty stream from vaccine sales [2] - Overabundant deer populations can double in size every two years, leading to ecological and agricultural challenges, making non-lethal population management methods like SpayVac increasingly relevant [2] - The company is also exploring trials with other species, including feral horses and Asian elephants, to expand the market for SpayVac [3] Group 3: Company Background - BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies [5][6] - The company is also advancing other immunotherapy products targeting various diseases, including cancer and allergies [6] - BioVaxys shares are listed on multiple exchanges, indicating a commitment to transparency and investor engagement [7]